2021-22年英国性传播广泛耐药宋内志贺菌暴发:一项描述性流行病学研究
2021年9月至2022年2月,英国通过常规实验室监测和全基因组测序单核苷酸多态性(SNP)分型识别出72例宋内志贺菌clade 5的十SNP单连锁簇病例,其中66例(92%)携带blaCTX-M-27(质粒介导的超广谱β-内酰胺酶基因),呈广泛耐药(XDR)特征。33例有临床数据的病例中19例(58%)接受抗生素治疗,8例(24%)住院;27例完成专项问卷的病例中21例(78%)为HIV阴性、正在使用HIV暴露前预防(PrEP)且报告在英国和欧洲有性接触的男男性行为者(MSM)。作者建议在临床有指征时加强志贺菌检测、抗菌药物耐药监测,并在所有MSM(包括PrEP使用者)中整合健康促进信息。
要点
- 2021年9月4日至2022年2月9日英国共识别72例宋内志贺菌clade 5十SNP单连锁簇病例,70例(97%)为男性,中位年龄34岁(IQR 27-39)。
- 72例中66例(92%)携带blaCTX-M-27,为质粒介导的超广谱β-内酰胺酶(ESBL)基因,分离株以广泛耐药(XDR)为主。
- 33例有临床数据的病例中19例(58%)接受抗生素治疗,8例(24%)住院;27例完成专项问卷者中21例(78%)为HIV阴性、使用HIV暴露前预防(PrEP)且报告在英国和欧洲有性接触的MSM。
核心结论
- 研究强调产ESBL的XDR宋内志贺菌在MSM性网络中快速传播。
- 作者建议在临床有指征时加强志贺菌检测、抗菌药物耐药监测,并在所有MSM(包括PrEP使用者)中整合健康促进信息,以减轻志贺菌病负担。
研究设计与样本
- 描述性流行病学研究,基于英国常规实验室监测(第二代监测系统、胃肠道数据仓库)发现2021年9月首次检测到的宋内志贺菌clade 5超出预期。
- 确诊病例定义为2021年9月1日至2022年2月9日标本日期、经基因组学确认属于十SNP连锁簇的英国宋内志贺菌clade 5感染者,病例随后报告自苏格兰、威尔士和北爱尔兰。
- 采用全基因组测序与SNP分型识别基因组簇和耐药决定因子,分析全英国病例。
- 通过问卷(标准和专项暴发问卷)收集英格兰宋内志贺菌clade 5感染者的人口学、流行病学和临床数据,使用描述性汇总统计量刻画病例特征。
主要发现
- 2021年9月4日至2022年2月9日共识别72例宋内志贺菌clade 5十SNP单连锁簇病例,其中70例(97%)为男性,中位年龄34岁(IQR 27-39)。
- 分离株以XDR为主,72例中66例(92%)携带blaCTX-M-27,为质粒介导的超广谱β-内酰胺酶(ESBL)基因。
- 33例有临床数据的病例中,19例(58%)接受抗生素治疗,8例(24%)住院。
- 27例完成专项暴发问卷的病例中,21例(78%)为HIV阴性、使用HIV暴露前预防(PrEP)且报告在 incubation period 内在英国和欧洲有性接触的MSM。
临床怎么用
- 作者建议在临床有指征时加强志贺菌检测。
- 作者建议加强抗菌药物耐药监测。
- 作者建议在所有MSM(包括PrEP使用者)中整合健康促进信息,以减轻志贺菌病负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shigellosis, traditionally a foodborne and waterborne infection, causes substantial morbidity globally. It is now a leading cause of sexually transmitted gastroenteritis among gay, bisexual, and other men who have sex with men (MSM). We describe an ongoing outbreak of extensively drug-resistant (XDR) Shigella sonnei in the UK. METHODS: Routine laboratory surveillance (Second Generation Surveillance System, Gastrointestinal Data Warehouse) identified an exceedance of S sonnei clade 5 in England, first detected in September, 2021. Cases within this clade were subsequently reported from Scotland, Wales, and Northern Ireland. Confirmed cases in this outbreak were defined as individuals diagnosed with S sonnei clade 5 in the UK, with a specimen date between Sept 1, 2021, and Feb 9, 2022, who were genomically confirmed as part of a ten-single nucleotide polymorphism (SNP) linkage cluster. We used whole-genome sequencing with SNP typing to identify genomic clusters and antimicrobial-resistance determinants, analysing cases across the UK. We collected demographic, epidemiological, and clinical data from people infected with S sonnei clade 5 in England using questionnaires (standard and bespoke outbreak questionnaires). We used descriptive summary statistics to characterise cases. FINDINGS: 72 cases (70 [97%] male, median age 34 years [IQR 27-39]) belonging to the ten-SNP single linkage cluster of S sonnei clade 5 were identified between Sept 4, 2021, and Feb 9, 2022. Isolates were predominantly XDR, with 66 (92%) of 72 harbouring blaCTX-M-27, a plasmid-mediated gene for production of extended-spectrum β-lactamases (ESBLs). Of 33 cases with clinical data, 19 (58%) received antibiotics and eight (24%) were hospitalised. 21 (78%) of 27 cases with completed bespoke outbreak questionnaires were HIV-negative MSM taking HIV pre-exposure prophylaxis (PrEP) who reported sexual contacts in the UK and Europe within the incubation period. INTERPRETATION: We highlight the rapid dissemination of XDR ESBL-producing S sonnei in sexual networks of MSM. We recommend strengthening shigella testing where clinically indicated, antimicrobial-resistance surveillance, and integrated health promotion messaging among all MSM, including PrEP users, to reduce the burden of shigellosis. FUNDING: National Institute for Health Research Health Protection Research Unit in Gastrointestinal Infections at the University of Liverpool in partnership with the UK Health Security Agency.
引用
- Charles H, Prochazka M, Thorley K, et al. Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study. Lancet Infect Dis. 2022. PMID: 35809593. doi:10.1016/S1473-3099(22)00370-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。